3.03  -0.09 (-2.88%)		01-22 16:00
Open: 3.12 High: 3.25 Volume: 231,447		Pre. Close: 3.12 Low: 2.98 Market Cap: 64(M)

Short term
Mid term
Targets	6-month :	6.14	1-year :	8.17
Resists	First :	5.26	Second :	7
Pivot price	4.24
Supports	First :	2.45	Second :	2.03
MAs	MA(5) :	3.52	MA(20) :	4.27
	MA(100) :	3.23	MA(250) :	0
MACD	MACD :	0	Signal :	0.2
%K %D	K(14,3) :	13.1	D(3) :	14.2
RSI	RSI(14): 41
52-week	High :	7	Low :	1.58

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ OSTX ] has closed above bottom band by 5.5%. Bollinger Bands are 90.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	3.24 - 3.26	3.26 - 3.28
Low:	2.94 - 2.95	2.95 - 2.97
Close:	3.01 - 3.04	3.04 - 3.07

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

Tue, 21 Jan 2025
OS Therapies Inc's Lock-Up Period Set To Expire on January 28th (NYSE:OSTX) - MarketBeat

Sat, 18 Jan 2025
Shalom Auerbach Sells 16,720 Shares of OS Therapies Inc (NYSE:OSTX) Stock - MarketBeat

Thu, 16 Jan 2025
OS Therapies: A Cheap Mid-Stage Biotech Carrying Listeria-Based Immunotherapy - Seeking Alpha

Wed, 15 Jan 2025
OS Therapies Incorporated announced that it expects to receive $10 million in funding -December 23, 2024 - Marketscreener.com

Wed, 15 Jan 2025
OS Therapies up 65% as lung osteosarcoma asset meets goal in phase 2 trial - Seeking Alpha

Wed, 15 Jan 2025
OS Therapies' OST-HER2 Achieves Breakthrough in Osteosarcoma Trial with 91% One-Year Survival Rate - StockTitan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NYSE
Sector: Healthcare
Industry: Biotechnology
Shares Out	21 (M)
Shares Float	17 (M)
Held by Insiders	24.8 (%)
Held by Institutions	0 (%)
Shares Short	9 (K)
Shares Short P.Month	0 (K)

EPS	-0.32
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-4.52
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.16
Qtrly Earnings Growth	0 %
Operating Cash Flow	-3 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	-9.54
PEG Ratio	0
Price to Book value	-0.68
Price to Sales	0
Price to Cash Flow	-19.48

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.